NVAX Novavax Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVAX

Price (delayed)

$8.525

Market cap

$1.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

$1.48B

?
Relative Growth: Rel. Growth: 16
Relative Strength: Rel. Strength: 61
Relative Valuation: Rel. Valuation: 14
Relative Profitability: Rel. Profitability: 21

Novavax, Inc. tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles. The ...

Highlights
Novavax's net income has plunged by 122% YoY but it has soared by 69% from the previous quarter
Novavax's EPS has shrunk by 122% YoY but it has surged by 70% QoQ
NVAX's gross profit has shrunk by 67% YoY
The revenue has plunged by 61% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novavax.com
Peers: SRPT AGEN EBS BCRX

Key stats

What are the main financial stats of NVAX

NVAX stock price

How has the Novavax stock price performed over time
Intraday
-2.68%
1 week
-20.92%
1 month
-33.5%
1 year
20.75%
YTD
26.86%
QTD
-21.14%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$411.65M
Gross profit
$321.12M
Operating income
-$87.39M
Net income
-$76.73M
Gross margin
78%
Net margin
-18.6%
The operating margin has dropped by 173% year-on-year but it has soared by 63% since the previous quarter
Novavax's net margin has shrunk by 158% YoY but it has surged by 69% QoQ
Novavax's operating income has plunged by 128% YoY but it has soared by 63% from the previous quarter
Novavax's net income has plunged by 122% YoY but it has soared by 69% from the previous quarter

Price vs fundamentals

How does NVAX's price correlate with its fundamentals

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
3.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.59
Novavax's EPS has shrunk by 122% YoY but it has surged by 70% QoQ
Novavax's equity has decreased by 38% YoY and by 14% QoQ
NVAX's P/S is 71% above its 5-year quarterly average of 2.0 and 22% above its last 4 quarters average of 2.8
The revenue has plunged by 61% YoY

Efficiency

How efficient is Novavax business performance
Novavax's return on sales has shrunk by 135% YoY but it has surged by 77% QoQ
NVAX's return on assets has dropped by 130% year-on-year but it has surged by 67% since the previous quarter
The ROIC has plunged by 112% YoY but it has soared by 77% from the previous quarter

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 20% lower than its total liabilities
Novavax's total assets has decreased by 25% YoY and by 7% QoQ
The total liabilities has declined by 17% year-on-year and by 3.6% since the previous quarter
Novavax's equity has decreased by 38% YoY and by 14% QoQ
Novavax's debt has increased by 18% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.